Floatz logo

Irinotecan

MSS Metastatic Colorectal Cancer

Shanghai EpimAb Biotherapeutics Co., Ltd.Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the MSS Metastatic Colorectal Cancer cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Oncolytics Biotech
Phase 2B
Zanubrutinib
Sun Yat-sen University
Phase 2CCC
Pelareorep
Oncolytics Biotech
Phase 2CCC
Fruquintinib
Ningbo Medical Center Lihuili Hospital
Phase 2CCC
Lubiprostone
Sun Yat-sen University
Phase 2CCC
cc-5013
Sun Yat-sen University
Phase 2CCC
Adebrelimab
Ningbo Medical Center Lihuili Hospital
D

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →